Migraine Prevention: CGRP Inhibitors, Comparative Efficacy, and Treatment Selection

Treatment Selection: Practical Framework

For patients who prefer oral medication and value dual acute/preventive utility, rimegepant offers a unique profile. For patients who prefer monthly self-injection, erenumab, galcanezumab, or fremanezumab are reasonable first choices. Fremanezumab uniquely offers a quarterly dosing option (675 mg SC every 3 months). For patients with severe chronic migraine desiring rapid onset, eptinezumab IV provides the fastest documented effect. Prior failure of 2-3 oral preventives (topiramate, beta-blockers, amitriptyline; see also chronic pain management) is typically required by US insurers before CGRP therapy authorization.

Navigating Insurance Access Barriers

The most common obstacle to CGRP therapy is not clinical but administrative. Most US insurers require documented failure of two to three traditional preventive medications before approving CGRP agents, and the documentation requirements can be burdensome. Clinicians should anticipate this process by maintaining clear records of prior preventive trial durations, doses reached, and reasons for discontinuation (inefficacy versus intolerance). Peer-to-peer appeals are frequently successful when the clinical rationale is clearly articulated. For patients with severe, disabling migraine who have failed multiple preventives, the prior authorization process is a frustrating but navigable barrier — and the effort is justified by the meaningful improvement in quality of life that CGRP therapy provides for appropriate candidates.

Safety Profile and Monitoring

Anti-CGRP mAbs have demonstrated a remarkably clean safety profile across open-label extension studies of up to 5 years. The most common adverse effects are injection-site reactions (erenumab, galcanezumab, fremanezumab) and constipation (erenumab, 3-4% vs 1% placebo)[7]. Hepatotoxicity is a theoretical concern with gepants based on early-generation oral CGRP antagonist data (telcagepant), but atogepant and rimegepant have not shown clinically significant hepatic signals. ALT monitoring is not required but reasonable in patients with baseline hepatic disease. No cardiovascular safety concerns have emerged (post-concussion headache is a common differential), though theoretical CGRP blockade effects on wound healing and Raynaud phenomenon warrant ongoing surveillance.

Setting Expectations with Patients

Patients starting CGRP preventive therapy should understand that the goal is meaningful reduction in migraine frequency, not elimination. Clinical trial response is typically defined as a reduction in monthly migraine days, and even highly effective agents leave most patients with some migraine days. Framing the discussion around realistic outcomes — "most patients see their migraine days cut roughly in half, and some do even better" — prevents disappointment and premature discontinuation. The assessment window matters too: most agents should be tried for at least three to four months before concluding they are ineffective, and some patients who show a modest initial response continue to improve over the first six months of treatment.

Limitations and Evolving Questions

Large head-to-head trials directly comparing CGRP monoclonal antibodies to each other are lacking, and the comparative efficacy data rely primarily on indirect treatment comparisons and network meta-analyses — methods that have inherent limitations. Whether long-term CGRP blockade has consequences beyond what is currently known remains an area of active surveillance, though the safety data through five-plus years of extension studies are reassuring. The optimal duration of CGRP preventive therapy is undefined — whether to continue indefinitely, attempt drug holidays, or cycle between agents — and reflects a broader uncertainty in migraine prevention about when and how to reassess ongoing therapy.

References

1. A Controlled Trial of Erenumab for Episodic Migraine (STRIVE)
2. Galcanezumab in patients with episodic migraine: results from the EVOLVE-1 randomized clinical trial
3. Trial of Eptinezumab for Migraine Prevention (PROMISE-1)
4. Atogepant for the Preventive Treatment of Migraine (ADVANCE)
5. Atogepant for the preventive treatment of chronic migraine (PROGRESS)
6. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
7. A Controlled Trial of Erenumab for Episodic Migraine (STRIVE)